 Jeffrey Kaplan
Concepts (378)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biofilms | 39 | 2025 | 260 | 9.380 |
Why?
| | Aggregatibacter actinomycetemcomitans | 22 | 2024 | 27 | 4.080 |
Why?
| | Staphylococcus epidermidis | 15 | 2025 | 77 | 3.350 |
Why?
| | Glycoside Hydrolases | 14 | 2025 | 26 | 3.220 |
Why?
| | Bacterial Proteins | 24 | 2025 | 879 | 3.020 |
Why?
| | Anti-Bacterial Agents | 17 | 2025 | 1809 | 2.350 |
Why?
| | Polysaccharides, Bacterial | 13 | 2015 | 70 | 2.200 |
Why?
| | Bacterial Adhesion | 18 | 2018 | 100 | 2.100 |
Why?
| | Staphylococcus aureus | 9 | 2018 | 450 | 1.830 |
Why?
| | Actinobacillus pleuropneumoniae | 5 | 2013 | 5 | 1.460 |
Why?
| | DNA, Bacterial | 11 | 2024 | 337 | 1.450 |
Why?
| | Kingella kingae | 3 | 2016 | 12 | 1.260 |
Why?
| | Microbial Sensitivity Tests | 10 | 2025 | 361 | 1.050 |
Why?
| | Acetylglucosamine | 6 | 2008 | 13 | 0.970 |
Why?
| | Benzoyl Peroxide | 1 | 2025 | 2 | 0.950 |
Why?
| | Propionibacteriaceae | 1 | 2025 | 2 | 0.950 |
Why?
| | Propionibacterium acnes | 1 | 2025 | 10 | 0.940 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2024 | 234 | 0.880 |
Why?
| | Micrococcal Nuclease | 1 | 2024 | 26 | 0.870 |
Why?
| | Actinobacillus Infections | 7 | 2008 | 7 | 0.850 |
Why?
| | Prosthesis-Related Infections | 6 | 2011 | 95 | 0.850 |
Why?
| | Deoxyribonuclease I | 5 | 2018 | 39 | 0.800 |
Why?
| | Adhesins, Bacterial | 6 | 2010 | 40 | 0.780 |
Why?
| | Bacteria | 5 | 2014 | 858 | 0.740 |
Why?
| | Extracellular Space | 2 | 2012 | 119 | 0.710 |
Why?
| | Amoxicillin | 2 | 2024 | 35 | 0.700 |
Why?
| | Povidone-Iodine | 2 | 2018 | 11 | 0.680 |
Why?
| | Staphylococcal Skin Infections | 1 | 2018 | 35 | 0.580 |
Why?
| | Molecular Sequence Data | 17 | 2012 | 2900 | 0.550 |
Why?
| | Cetylpyridinium | 4 | 2009 | 6 | 0.530 |
Why?
| | Neisseriaceae Infections | 2 | 2016 | 6 | 0.520 |
Why?
| | beta-Lactams | 2 | 2016 | 33 | 0.500 |
Why?
| | Virulence Factors | 3 | 2024 | 167 | 0.470 |
Why?
| | Exotoxins | 4 | 2008 | 16 | 0.450 |
Why?
| | Pasteurellaceae | 3 | 2010 | 3 | 0.440 |
Why?
| | Genome, Bacterial | 2 | 2012 | 142 | 0.420 |
Why?
| | Genes, Bacterial | 5 | 2004 | 164 | 0.420 |
Why?
| | Bacterial Capsules | 1 | 2013 | 30 | 0.410 |
Why?
| | Arthritis, Infectious | 1 | 2012 | 69 | 0.360 |
Why?
| | Sodium Dodecyl Sulfate | 2 | 2009 | 26 | 0.350 |
Why?
| | Drug Resistance, Bacterial | 4 | 2018 | 186 | 0.350 |
Why?
| | Pasteurellaceae Infections | 2 | 2024 | 2 | 0.350 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 938 | 0.340 |
Why?
| | Recombination, Genetic | 1 | 2011 | 204 | 0.340 |
Why?
| | Fimbriae, Bacterial | 3 | 2016 | 34 | 0.340 |
Why?
| | Extracellular Matrix | 2 | 2014 | 528 | 0.340 |
Why?
| | Periodontitis | 5 | 2006 | 53 | 0.330 |
Why?
| | Staphylococcus | 2 | 2007 | 76 | 0.330 |
Why?
| | Enzyme Therapy | 1 | 2009 | 4 | 0.320 |
Why?
| | beta-Glucans | 1 | 2008 | 20 | 0.310 |
Why?
| | Mouth | 2 | 2015 | 87 | 0.300 |
Why?
| | Polysaccharides | 2 | 2008 | 79 | 0.300 |
Why?
| | Aggressive Periodontitis | 3 | 2003 | 4 | 0.300 |
Why?
| | Down-Regulation | 1 | 2011 | 657 | 0.300 |
Why?
| | Disinfectants | 1 | 2009 | 39 | 0.300 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 63 | 0.290 |
Why?
| | Mouth Mucosa | 2 | 2007 | 92 | 0.290 |
Why?
| | Fusobacterium nucleatum | 1 | 2008 | 4 | 0.290 |
Why?
| | Dental Plaque | 1 | 2008 | 18 | 0.290 |
Why?
| | Bacterial Infections | 1 | 2010 | 250 | 0.280 |
Why?
| | Adenocarcinoma | 3 | 2024 | 940 | 0.280 |
Why?
| | Cefamandole | 1 | 2007 | 1 | 0.280 |
Why?
| | Galactans | 1 | 2007 | 4 | 0.270 |
Why?
| | Polyurethanes | 1 | 2007 | 38 | 0.270 |
Why?
| | Bacterial Physiological Phenomena | 3 | 2014 | 61 | 0.270 |
Why?
| | Humans | 45 | 2025 | 137585 | 0.260 |
Why?
| | Sequence Analysis, DNA | 6 | 2009 | 812 | 0.260 |
Why?
| | Surface-Active Agents | 1 | 2007 | 91 | 0.260 |
Why?
| | Drug Resistance | 1 | 2007 | 169 | 0.250 |
Why?
| | Swine Diseases | 1 | 2005 | 8 | 0.240 |
Why?
| | Recombinant Proteins | 5 | 2018 | 1353 | 0.240 |
Why?
| | O Antigens | 2 | 2003 | 9 | 0.240 |
Why?
| | Acne Vulgaris | 1 | 2025 | 29 | 0.230 |
Why?
| | Fimbriae Proteins | 3 | 2016 | 21 | 0.230 |
Why?
| | Drug Synergism | 1 | 2025 | 382 | 0.220 |
Why?
| | Serotyping | 4 | 2008 | 32 | 0.220 |
Why?
| | Species Specificity | 4 | 2011 | 585 | 0.210 |
Why?
| | Acetylglucosaminidase | 1 | 2003 | 5 | 0.210 |
Why?
| | Animals | 17 | 2024 | 36940 | 0.210 |
Why?
| | Genetic Variation | 3 | 2002 | 991 | 0.200 |
Why?
| | Neisseria | 1 | 2002 | 2 | 0.200 |
Why?
| | Bacteria, Anaerobic | 1 | 2002 | 25 | 0.190 |
Why?
| | Base Sequence | 6 | 2012 | 2181 | 0.190 |
Why?
| | Gene Transfer, Horizontal | 2 | 2016 | 34 | 0.180 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 68 | 0.180 |
Why?
| | Gram-Negative Bacteria | 1 | 2001 | 73 | 0.170 |
Why?
| | Barrett Esophagus | 1 | 2023 | 149 | 0.170 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 1062 | 0.170 |
Why?
| | Gastroesophageal Reflux | 1 | 2023 | 234 | 0.170 |
Why?
| | Amino Acid Sequence | 7 | 2008 | 2139 | 0.170 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2021 | 161 | 0.170 |
Why?
| | Osteopontin | 1 | 2020 | 33 | 0.170 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 39 | 0.170 |
Why?
| | Macrophages | 1 | 2008 | 1547 | 0.170 |
Why?
| | Microfluidics | 2 | 2010 | 54 | 0.160 |
Why?
| | Codon | 2 | 1998 | 89 | 0.160 |
Why?
| | DNA Transposable Elements | 4 | 2008 | 121 | 0.160 |
Why?
| | Polystyrenes | 3 | 2004 | 35 | 0.160 |
Why?
| | Esophageal Neoplasms | 1 | 2023 | 321 | 0.150 |
Why?
| | Microfluidic Analytical Techniques | 2 | 2010 | 77 | 0.150 |
Why?
| | Sus scrofa | 1 | 2018 | 52 | 0.150 |
Why?
| | Escherichia coli | 5 | 2010 | 815 | 0.140 |
Why?
| | Colony Count, Microbial | 2 | 2009 | 120 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 21 | 0.140 |
Why?
| | Weight Gain | 1 | 2021 | 519 | 0.140 |
Why?
| | Liver | 2 | 2020 | 1943 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2018 | 60 | 0.130 |
Why?
| | Epithelial Cells | 3 | 2010 | 1096 | 0.130 |
Why?
| | Adipose Tissue | 1 | 2021 | 635 | 0.130 |
Why?
| | Endopeptidase K | 1 | 2016 | 17 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 279 | 0.130 |
Why?
| | Biopsy | 2 | 2018 | 1129 | 0.130 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 116 | 0.130 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 362 | 0.130 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 9 | 0.120 |
Why?
| | Mutagenesis, Insertional | 3 | 2008 | 65 | 0.120 |
Why?
| | Myositis | 1 | 2015 | 52 | 0.120 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.120 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 400 | 0.120 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 21 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2016 | 132 | 0.110 |
Why?
| | Air | 1 | 2014 | 37 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 155 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 61 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2001 | 1164 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2007 | 611 | 0.110 |
Why?
| | Bone Resorption | 1 | 2015 | 86 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2015 | 145 | 0.110 |
Why?
| | Environmental Microbiology | 1 | 2014 | 53 | 0.110 |
Why?
| | Anilides | 1 | 2014 | 73 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2014 | 171 | 0.110 |
Why?
| | Plankton | 1 | 2014 | 6 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2057 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2019 | 786 | 0.100 |
Why?
| | Surface Properties | 4 | 2012 | 413 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 209 | 0.100 |
Why?
| | Molecular Weight | 1 | 2013 | 335 | 0.100 |
Why?
| | Female | 15 | 2024 | 73304 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3412 | 0.100 |
Why?
| | Pancreas | 1 | 2014 | 329 | 0.090 |
Why?
| | Coated Materials, Biocompatible | 1 | 2012 | 62 | 0.090 |
Why?
| | Cell Survival | 3 | 2012 | 1120 | 0.090 |
Why?
| | Tobramycin | 1 | 2011 | 52 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4295 | 0.090 |
Why?
| | Microscopy, Electron | 2 | 2003 | 443 | 0.090 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2014 | 289 | 0.090 |
Why?
| | Cell Communication | 1 | 2013 | 315 | 0.090 |
Why?
| | Genetic Complementation Test | 2 | 2008 | 67 | 0.090 |
Why?
| | Orthopedic Equipment | 1 | 2010 | 5 | 0.090 |
Why?
| | Culture Media | 3 | 2010 | 165 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1276 | 0.090 |
Why?
| | Pyridines | 1 | 2014 | 506 | 0.090 |
Why?
| | Treatment Failure | 1 | 2011 | 356 | 0.080 |
Why?
| | Focal Nodular Hyperplasia | 1 | 2010 | 8 | 0.080 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2007 | 58 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2002 | 549 | 0.080 |
Why?
| | Fungi | 1 | 2011 | 144 | 0.080 |
Why?
| | Bacterial Toxins | 2 | 2002 | 106 | 0.080 |
Why?
| | Escherichia coli Proteins | 1 | 2011 | 200 | 0.080 |
Why?
| | DNA Primers | 2 | 2007 | 515 | 0.080 |
Why?
| | Titanium | 1 | 2010 | 82 | 0.080 |
Why?
| | Disease Transmission, Infectious | 1 | 2010 | 62 | 0.080 |
Why?
| | Osteoblasts | 1 | 2010 | 126 | 0.080 |
Why?
| | Sodium Hypochlorite | 1 | 2009 | 4 | 0.080 |
Why?
| | Drug Interactions | 2 | 2008 | 410 | 0.080 |
Why?
| | Convection | 1 | 2008 | 6 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 143 | 0.080 |
Why?
| | Enzymes | 1 | 2009 | 67 | 0.080 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2008 | 385 | 0.080 |
Why?
| | Mutation | 5 | 2009 | 3958 | 0.080 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 328 | 0.080 |
Why?
| | Chlorhexidine | 1 | 2009 | 24 | 0.080 |
Why?
| | Flagella | 1 | 1989 | 27 | 0.080 |
Why?
| | Azo Compounds | 1 | 2008 | 30 | 0.080 |
Why?
| | Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2008 | 4 | 0.070 |
Why?
| | Diffusion | 1 | 2008 | 116 | 0.070 |
Why?
| | Catalytic Domain | 2 | 2008 | 207 | 0.070 |
Why?
| | Caenorhabditis elegans | 1 | 2011 | 306 | 0.070 |
Why?
| | Pancreatectomy | 2 | 2024 | 253 | 0.070 |
Why?
| | Male | 12 | 2024 | 67762 | 0.070 |
Why?
| | Phylogeny | 2 | 2002 | 904 | 0.070 |
Why?
| | Obesity | 1 | 2021 | 2992 | 0.070 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2007 | 11 | 0.070 |
Why?
| | Congo Red | 1 | 2007 | 9 | 0.070 |
Why?
| | Gene Order | 1 | 2007 | 26 | 0.070 |
Why?
| | Tritium | 1 | 2007 | 76 | 0.070 |
Why?
| | Detergents | 1 | 2007 | 44 | 0.070 |
Why?
| | Micelles | 1 | 2007 | 39 | 0.070 |
Why?
| | Quorum Sensing | 1 | 2008 | 77 | 0.070 |
Why?
| | Chromosomes, Bacterial | 1 | 2007 | 7 | 0.070 |
Why?
| | Ampicillin | 1 | 2007 | 13 | 0.070 |
Why?
| | Glycosyltransferases | 1 | 2007 | 11 | 0.070 |
Why?
| | Periodic Acid | 1 | 2007 | 2 | 0.070 |
Why?
| | Pancreatin | 1 | 2007 | 6 | 0.070 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2006 | 4 | 0.070 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2006 | 4 | 0.070 |
Why?
| | Ligands | 2 | 2008 | 664 | 0.070 |
Why?
| | Middle Aged | 8 | 2024 | 33479 | 0.070 |
Why?
| | Carbohydrate Sequence | 2 | 2008 | 27 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2014 | 806 | 0.060 |
Why?
| | Peptide Hydrolases | 1 | 2007 | 111 | 0.060 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2607 | 0.060 |
Why?
| | Pleuropneumonia | 1 | 2005 | 1 | 0.060 |
Why?
| | Carbohydrate Conformation | 1 | 2005 | 11 | 0.060 |
Why?
| | Hydrogels | 2 | 2012 | 678 | 0.060 |
Why?
| | Gene Deletion | 1 | 2007 | 391 | 0.060 |
Why?
| | Virulence | 2 | 2003 | 267 | 0.060 |
Why?
| | Static Electricity | 1 | 2005 | 118 | 0.060 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 201 | 0.060 |
Why?
| | Mice | 5 | 2021 | 17787 | 0.060 |
Why?
| | Aged | 6 | 2024 | 23961 | 0.060 |
Why?
| | Carbohydrate Metabolism | 1 | 2004 | 59 | 0.050 |
Why?
| | Primates | 1 | 2005 | 126 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 374 | 0.050 |
Why?
| | Child, Preschool | 2 | 2016 | 11074 | 0.050 |
Why?
| | Lactoferrin | 1 | 2003 | 31 | 0.050 |
Why?
| | Adult | 7 | 2020 | 37929 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 179 | 0.050 |
Why?
| | Metaplasia | 1 | 2023 | 60 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 641 | 0.050 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1457 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2129 | 0.050 |
Why?
| | Sequence Analysis, Protein | 1 | 2002 | 30 | 0.050 |
Why?
| | Agar | 1 | 2002 | 12 | 0.050 |
Why?
| | Child | 3 | 2016 | 21935 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 861 | 0.050 |
Why?
| | Bacteriological Techniques | 1 | 2003 | 73 | 0.050 |
Why?
| | Swine | 1 | 2005 | 775 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1250 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2002 | 239 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2010 | 871 | 0.050 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 88 | 0.050 |
Why?
| | Mice, Obese | 1 | 2021 | 66 | 0.050 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 54 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 404 | 0.050 |
Why?
| | Esophagoscopy | 1 | 2023 | 209 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2003 | 378 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1389 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 91 | 0.040 |
Why?
| | Phenotype | 2 | 2010 | 3196 | 0.040 |
Why?
| | Genotype | 2 | 2003 | 1916 | 0.040 |
Why?
| | Tamoxifen | 1 | 2021 | 202 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1670 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2001 | 146 | 0.040 |
Why?
| | Protein Precursors | 1 | 2001 | 134 | 0.040 |
Why?
| | Mutagenesis | 1 | 2001 | 179 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1783 | 0.040 |
Why?
| | Coculture Techniques | 2 | 2010 | 239 | 0.040 |
Why?
| | Alleles | 1 | 2002 | 891 | 0.040 |
Why?
| | Temperature | 1 | 2002 | 679 | 0.040 |
Why?
| | Adolescent | 4 | 2010 | 21513 | 0.040 |
Why?
| | Protein Binding | 1 | 2005 | 2224 | 0.040 |
Why?
| | ROC Curve | 1 | 2020 | 554 | 0.040 |
Why?
| | Genetic Code | 1 | 1998 | 22 | 0.040 |
Why?
| | Base Composition | 1 | 1998 | 78 | 0.040 |
Why?
| | Infant | 1 | 2012 | 9465 | 0.040 |
Why?
| | Cyst Fluid | 1 | 2018 | 25 | 0.040 |
Why?
| | Carcinoembryonic Antigen | 1 | 2018 | 39 | 0.040 |
Why?
| | Hydrolysis | 2 | 2008 | 177 | 0.040 |
Why?
| | Cell Movement | 1 | 2002 | 967 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2010 | 2654 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2018 | 51 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2018 | 56 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2008 | 372 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7635 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 976 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1079 | 0.030 |
Why?
| | Endosonography | 1 | 2018 | 156 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 39 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 24 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 10811 | 0.030 |
Why?
| | Cell Line | 2 | 2012 | 2847 | 0.030 |
Why?
| | Binding Sites | 2 | 2010 | 1303 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 220 | 0.030 |
Why?
| | CD3 Complex | 1 | 2015 | 106 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1692 | 0.030 |
Why?
| | Monosaccharides | 1 | 2014 | 12 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 389 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1946 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2014 | 80 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2015 | 2486 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 219 | 0.030 |
Why?
| | Intestine, Small | 1 | 2015 | 156 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 95 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 6828 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 971 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 187 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 956 | 0.030 |
Why?
| | Lymphocytes | 1 | 2015 | 397 | 0.030 |
Why?
| | Microscopy | 1 | 2014 | 152 | 0.030 |
Why?
| | Colon | 1 | 2015 | 282 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 822 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 955 | 0.020 |
Why?
| | Models, Molecular | 2 | 2008 | 1570 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 229 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 301 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 698 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2757 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3556 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2014 | 366 | 0.020 |
Why?
| | Polymethacrylic Acids | 1 | 2012 | 62 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 437 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1587 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1774 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 872 | 0.020 |
Why?
| | Rats | 2 | 2015 | 5647 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1972 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1483 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1178 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5757 | 0.020 |
Why?
| | Propidium | 1 | 2010 | 8 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2010 | 163 | 0.020 |
Why?
| | Cell Shape | 1 | 2010 | 57 | 0.020 |
Why?
| | Alloys | 1 | 2010 | 35 | 0.020 |
Why?
| | Siphoviridae | 1 | 2009 | 2 | 0.020 |
Why?
| | Artificial Gene Fusion | 1 | 2009 | 3 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2009 | 5 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 363 | 0.020 |
Why?
| | Protein Hydrolysates | 1 | 2008 | 6 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 466 | 0.020 |
Why?
| | Caseins | 1 | 2008 | 20 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2009 | 269 | 0.020 |
Why?
| | Nucleotides | 1 | 2009 | 125 | 0.020 |
Why?
| | Buffers | 1 | 2008 | 56 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1396 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 402 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 886 | 0.020 |
Why?
| | Oligosaccharides | 1 | 2008 | 60 | 0.020 |
Why?
| | Multigene Family | 1 | 1989 | 198 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2008 | 201 | 0.020 |
Why?
| | Orthopedics | 1 | 2010 | 144 | 0.020 |
Why?
| | Rifampin | 1 | 2008 | 84 | 0.020 |
Why?
| | Microscopy, Atomic Force | 1 | 2008 | 126 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 390 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2008 | 142 | 0.020 |
Why?
| | Cercopithecidae | 1 | 2007 | 9 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 343 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2008 | 234 | 0.020 |
Why?
| | Phosphates | 1 | 2008 | 182 | 0.020 |
Why?
| | Teichoic Acids | 1 | 2007 | 14 | 0.020 |
Why?
| | Abortion, Eugenic | 1 | 2006 | 3 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 375 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 206 | 0.020 |
Why?
| | Equipment Design | 1 | 2008 | 522 | 0.020 |
Why?
| | Knee Prosthesis | 1 | 2006 | 27 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 2006 | 46 | 0.020 |
Why?
| | Thermodynamics | 1 | 2008 | 407 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 580 | 0.020 |
Why?
| | Genome Components | 1 | 2006 | 2 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2010 | 423 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 560 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 4030 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 303 | 0.020 |
Why?
| | Protein Transport | 1 | 2007 | 445 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2012 | 1991 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 162 | 0.010 |
Why?
| | Calcium | 1 | 2010 | 1199 | 0.010 |
Why?
| | Spodoptera | 1 | 2003 | 40 | 0.010 |
Why?
| | Computer Simulation | 1 | 2008 | 978 | 0.010 |
Why?
| | Alveolar Bone Loss | 1 | 2003 | 9 | 0.010 |
Why?
| | Genetic Testing | 1 | 2006 | 460 | 0.010 |
Why?
| | Maxilla | 1 | 2003 | 38 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 534 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2475 | 0.010 |
Why?
| | Adenosine Triphosphatases | 1 | 2003 | 168 | 0.010 |
Why?
| | Iron | 1 | 2003 | 313 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 5079 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1989 | 2833 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2003 | 660 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1459 | 0.010 |
Why?
| | United States | 1 | 2016 | 14841 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 15657 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6079 | 0.010 |
Why?
| | Pregnancy | 1 | 2006 | 6763 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2006 | 2111 | 0.010 |
Why?
|
|
Kaplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|